DSpace Repository

Is it cost-effective to use a low molecular weight (LMWH)-enoxaparin as prophylaxis in medical and surgical patients at risk for a venous thromboembolic event when compared with subcutaneous unfractione low dose heparin in South Africa

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)